MASITINIB · AB07002
Public neurological clinical research study information. Check the current recruitment status in the live Wix study record.
A 96-week, prospective, multicenter, randomised, double-blind, placebo-controlled, 2-parallel groups, Phase 3 study to compare efficacy and safety of masitinib 4.5 mg/kg/day versus placebo in the treatment of patients with primary progressive or relapse-free secondary progressive multiple sclerosis
Sponsor: AB SCIENCE
Phase: III
Area: Neuroimmunology